346 related articles for article (PubMed ID: 15879128)
1. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
2. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
3. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.
Palmowski MJ; Choi EM; Hermans IF; Gilbert SC; Chen JL; Gileadi U; Salio M; Van Pel A; Man S; Bonin E; Liljestrom P; Dunbar PR; Cerundolo V
J Immunol; 2002 May; 168(9):4391-8. PubMed ID: 11970981
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
[TBL] [Abstract][Full Text] [Related]
5. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.
Casares N; Lasarte JJ; de Cerio AL; Sarobe P; Ruiz M; Melero I; Prieto J; Borrás-Cuesta F
Eur J Immunol; 2001 Jun; 31(6):1780-9. PubMed ID: 11385623
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.
Song MK; Lee SW; Suh YS; Lee KJ; Sung YC
J Virol; 2000 Mar; 74(6):2920-5. PubMed ID: 10684312
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
Eo SK; Gierynska M; Kamar AA; Rouse BT
J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
[TBL] [Abstract][Full Text] [Related]
9. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
10. Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen.
Schirmbeck R; Zheng X; Roggendorf M; Geissler M; Chisari FV; Reimann J; Lu M
J Immunol; 2001 Jan; 166(2):1405-13. PubMed ID: 11145726
[TBL] [Abstract][Full Text] [Related]
11. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
Allen TM; Vogel TU; Fuller DH; Mothé BR; Steffen S; Boyson JE; Shipley T; Fuller J; Hanke T; Sette A; Altman JD; Moss B; McMichael AJ; Watkins DI
J Immunol; 2000 May; 164(9):4968-78. PubMed ID: 10779808
[TBL] [Abstract][Full Text] [Related]
12. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.
Sedegah M; Weiss W; Sacci JB; Charoenvit Y; Hedstrom R; Gowda K; Majam VF; Tine J; Kumar S; Hobart P; Hoffman SL
J Immunol; 2000 Jun; 164(11):5905-12. PubMed ID: 10820272
[TBL] [Abstract][Full Text] [Related]
13. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor.
Iwasaki A; Barber BH
Cancer Immunol Immunother; 1998 Jan; 45(5):273-9. PubMed ID: 9439651
[TBL] [Abstract][Full Text] [Related]
14. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
16. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
[TBL] [Abstract][Full Text] [Related]
17. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
[TBL] [Abstract][Full Text] [Related]
18. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.
Santra S; Barouch DH; Jackson SS; Kuroda MJ; Schmitz JE; Lifton MA; Sharpe AH; Letvin NL
J Immunol; 2000 Dec; 165(12):6791-5. PubMed ID: 11120800
[TBL] [Abstract][Full Text] [Related]
19. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
[TBL] [Abstract][Full Text] [Related]
20. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
